CA2128536A1 - Azabicyclo compounds as calcium channel antagonists - Google Patents

Azabicyclo compounds as calcium channel antagonists

Info

Publication number
CA2128536A1
CA2128536A1 CA002128536A CA2128536A CA2128536A1 CA 2128536 A1 CA2128536 A1 CA 2128536A1 CA 002128536 A CA002128536 A CA 002128536A CA 2128536 A CA2128536 A CA 2128536A CA 2128536 A1 CA2128536 A1 CA 2128536A1
Authority
CA
Canada
Prior art keywords
formula
compound
azabicyclo
heptane
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002128536A
Other languages
English (en)
French (fr)
Inventor
Barry S. Orlek
Thomas H. Brown
David G. Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2128536A1 publication Critical patent/CA2128536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002128536A 1992-01-28 1993-01-27 Azabicyclo compounds as calcium channel antagonists Abandoned CA2128536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929201751A GB9201751D0 (en) 1992-01-28 1992-01-28 Compounds
GB9201751.6 1992-01-28
PCT/GB1993/000174 WO1993015080A1 (en) 1992-01-28 1993-01-27 Azabicyclo compounds as calcium channel antagonists

Publications (1)

Publication Number Publication Date
CA2128536A1 true CA2128536A1 (en) 1993-08-05

Family

ID=10709351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002128536A Abandoned CA2128536A1 (en) 1992-01-28 1993-01-27 Azabicyclo compounds as calcium channel antagonists

Country Status (9)

Country Link
EP (1) EP0625981A1 (ko)
JP (1) JPH07503462A (ko)
KR (1) KR950700305A (ko)
AU (1) AU3364593A (ko)
CA (1) CA2128536A1 (ko)
GB (1) GB9201751D0 (ko)
MX (1) MX9300406A (ko)
WO (1) WO1993015080A1 (ko)
ZA (1) ZA93549B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
DK1345937T3 (da) 2000-12-22 2006-01-16 Almirall Prodesfarma Ag Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
MX2010003375A (es) 2007-10-01 2010-05-17 Comentis Inc Derivados de 1h-indol-3-carboxilato de quinuclidin-4-ilmetilo como ligandos del receptor de acetilcolina alfa 7 nicotinico para el tratamiento de enfermedad de alzheimer.
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (ko) * 1969-03-03 1971-10-20
GB9005737D0 (en) * 1990-03-14 1990-05-09 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
EP0625981A1 (en) 1994-11-30
KR950700305A (ko) 1995-01-16
JPH07503462A (ja) 1995-04-13
ZA93549B (en) 1994-09-22
AU3364593A (en) 1993-09-01
MX9300406A (es) 1994-07-29
GB9201751D0 (en) 1992-03-11
WO1993015080A1 (en) 1993-08-05

Similar Documents

Publication Publication Date Title
CA2226292C (en) Substituted benzolactam compounds as substance p antagonists
JP2500279B2 (ja) アザ二環式化合物、これを含有する医薬組成物及び治療のための使用方法
EP0625979A1 (en) Azabricyclic compounds as calcium channel antagonists
CA2128536A1 (en) Azabicyclo compounds as calcium channel antagonists
NZ192175A (en) Preparation of dextrorotatory trans 4a,9b-2-substituted-5--aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido-(4,3-b)indoles
JP2674199B2 (ja) 二環式アミン化合物およびその製造法
NL193541C (nl) 8 Alfa-acylaminoergolinen, werkwijzen voor de bereiding daarvan en preparaten die ze bevatten.
US3976660A (en) Pyrrolidine derivatives
FI71936B (fi) Foerfarande foer framstaellning av neuroleptiskt aktiva 2-substituerade-8-fluor-5-(4-fluorfenyl)-2,3,4,4a 5,9b-hexahydro-4a 9b-trans-1h-pyrido/4,3-b/indolderivat
US4033969A (en) Vincamine derivatives
EP0710237A1 (en) Quinolizidines with calcium channel antagonistic activity
AU610492B2 (en) 5-substituted octahydroindolizine analgesics compounds and 7-keto intermediates
PL141501B1 (en) Method of obtaining novel derivatives of quinoline and indene
IE49800B1 (en) Benzimidazolone derivatives,process for their preparation and pharmaceutical compositions containing them
US4665076A (en) Pharmacologically active piperidine derivatives and their use
US6288225B1 (en) Substituted benzolactam compounds as substance P antagonists
IE58121B1 (en) 1,3-Disubstituted piperdine compounds as neuroleptic agents
HU196388B (en) Process for preparing derivatives of dibenzo/be/oxepinylaeacetic acid derivatives and pharmaceutical compositions containing such compounds
US3583997A (en) Benzothiopyrano(2,3-c)pyridines
KR830001667B1 (ko) 페닐 퀴놀리지딘의 제조방법
US4123545A (en) N-Propyl-3(β-hydroxyethyl)-3-(meta-hydroxyphenyl)-pyrrolidine
US4784996A (en) Pyrimidoindoles useful as hypoglycaemics
US3385846A (en) Nu-cycloalkyl-azabicyclooctanes and-nonanes and nu-(2-cycloalken-1-yl)-azabicyclooctane and -nonane intermediates
US4800207A (en) Hexahydropyrrolizine compounds useful as analgesics
US4751238A (en) Substituted alkyl amine derivatives of 6,11-dihydro-11-oxodibenz[b,e]oxepins

Legal Events

Date Code Title Description
FZDE Dead